Lorexys
AssetAlso Lorexys low-dose, Lorexys moderate-dose
Norepinephrine and dopamine reuptake inhibitor formulation
- Stage
- Phase 1
- Modality
- Small molecule
- Target
- SLC6A2
- 2
- Indications
- 219
- Trials
- 1
- Developer
Indications
2Hypoactive sexual desire disorder
Phase 1, Completed, NCT01857596, clinicaltrials.gov, 8 Oct 2026
Sexual interest arousal disorder
Phase 1, Completed, NCT01857596, clinicaltrials.gov, 8 Oct 2026
In the full profile
- Targets and what it contains3
- Owner and partners1
- Trials219
- Evidence for its targets3
- Competitors7
- Signals3
Every asset’s record: target, stage, trials and the evidence behind it.